Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Klea HoldingVMDGF 36 Debt-to-EBITDA is 1.02 as of Dec. 2025. GuruFocus rates VMDGF with a GF Score™ of 36/100 and a GF Value™ of $0.43. The stock has 2 warning signs investors should review. Among 112 Medical Diagnostics & Research companies, Klea Holding ranks better than 66.96% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Klea Holding's Debt-to-EBITDA or its related term are showing as below:
VMDGF'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: -2.54 Med: -0.07 Max: 1.51
Current: 1.01
During the past 13 years, the highest Debt-to-EBITDA Ratio of Klea Holding was 1.51. The lowest was -2.54. And the median was -0.07.
VMDGF's Debt-to-EBITDA is ranked better than 66.96% of 112
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.31
vs VMDGF: 1.01
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Klea Holding Debt-to-EBITDA Related Terms
Klea Holding Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Klea Holding's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VMDGF vs TMO, DHR, IDXX: Debt-to-EBITDA Comparison
For the Diagnostics & Research subindustry, Klea Holding's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Klea Holding Debt-to-EBITDA vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Klea Holding's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Klea Holding's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is two times the quarterly (Dec. 2025) EBITDA data.
Klea Holding (VMDGF) has a Debt-to-EBITDA of 1.02 as of Dec. 2025. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Klea Holding. According to the industry distribution chart, Klea Holding ranks #37 out of 112 companies in the Medical Diagnostics & Research industry, placing it in the top 33%.
Is Klea Holding's Debt-to-EBITDA too high?
Klea Holding's current Debt-to-EBITDA is 1.02. The Medical Diagnostics & Research industry median Debt-to-EBITDA is 2.31. Klea Holding's value of 1.02 is 55.8% below this industry median. Based on the distribution chart, Klea Holding ranks #37 out of 112 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Klea Holding has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.
How does Klea Holding's Debt-to-EBITDA compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Klea Holding ranks #37 out of 112 companies for Debt-to-EBITDA. This puts Klea Holding in the upper half of its industry. The industry median Debt-to-EBITDA is 2.31. Klea Holding's value of 1.02 is 55.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Medical Diagnostics & Research company?
The median Debt-to-EBITDA among Medical Diagnostics & Research companies is 2.31, based on 112 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Klea Holding's current Debt-to-EBITDA of 1.02 is 55.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Klea Holding. For the Medical Diagnostics & Research industry, the median Debt-to-EBITDA is 2.31 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Klea Holding's current Debt-to-EBITDA is 1.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Klea Holding stock overvalued right now?
Klea Holding (VMDGF) has a current Debt-to-EBITDA of 1.02. The stock's GF Value™ is $0.43, compared to a current price of $0.20 — trading 53.5% below its estimated fair value. The current Debt-to-EBITDA is 1.02 and 55.8% below the Medical Diagnostics & Research industry median of 2.31. Klea Holding's overall GF Score™ is 36/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Klea Holding (VMDGF), the current Debt-to-EBITDA is 1.02 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Klea Holding (VMDGF) Overvalued in 2026?
Based on GuruFocus' analysis, Klea Holding stock appears to be undervalued.
The current stock price of $0.20 is trading 53.5% below its estimated GF Value™ of $0.43.
Key valuation signals for VMDGF:
Debt-to-EBITDA: 1.02
GF Value™: $0.43 vs. price of $0.20 (53.5% below fair value)
Industry Position: 55.8% below the Medical Diagnostics & Research median (#37 of 112)
No single metric tells the full story. See the VMDGF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Klea Holding focused on the acquisition, development and digitalization of companies in multiple sectors. Its development of Smart Salem, the first network of digital medical analysis centers accredited by the Dubai Ministry of Health (DHA) in the Emirates United Arabs, or its Smart Health joint venture developed in Saudi Arabia.
36GF Score
Get the complete analysis for VMDGF
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VMDGF has been successfully added to your 
